Angion Biomedica Corp.

47 articles with Angion Biomedica Corp.

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.

• Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

  8/3/2021

  Angion Biomedica Corp announced positive results from its Phase 1 study in healthy volunteers for ANG-3070, a novel oral tyrosine kinase receptor inhibitor being developed for the treatment of fibrotic diseases.

• 

  Clinical Catch-Up: June 28-July 2

  7/6/2021

  It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.

• Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

  6/29/2021

  Angion Biomedica Corp. (NASDAQ:ANGN), today announced that its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet the primary or secondary efficacy endpoints.

• Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

  5/17/2021

  Angion Biomedica Corp, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, provided a corporate update and reported financial results for the quarter ended March 31, 2021.

• Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

  4/29/2021

  Vifor Pharma and Angion Biomedica Corp., announced completion of enrollment for Angion’s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury.

• Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney InjuryTopline data expected in the second half of 2021

  4/29/2021

  Angion Biomedica Corp and Vifor Pharma announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury.

• Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

  3/30/2021

  Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2020.

• Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated PneumoniaTopline data expected in the first half of 2021

  3/25/2021

  Angion Biomedica Corp. announced completion of enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respiratory distress syndrome, or ARDS.

• Angion to Participate in Upcoming March 2021 Investment Conferences

  2/24/2021

  Angion Biomedica Corp., a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced its management team will present at the H.C. Wainwright Global Life Sciences Conference and the Oppenheimer 31st Annual Healthcare Conference.

• Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  2/9/2021

  Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of $117 million in gross proceeds from its previously announced initial public offering and concurrent private placement.

• Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

  2/5/2021

  Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million,

• 

  Clinical Catch-Up: July 6-10

  7/13/2020

  Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
• 

  BioSpace Movers & Shakers, June 5

  6/5/2020

  Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
• 

  Clinical Catch-Up: December 16-20

  12/23/2019

  Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
• 

  Clinical Catch-Up: November 4-8

  11/11/2019

  It was a busy week for clinical trial updates for the first week of November. Here’s a look.
• 

  Angion Biomedica Nears End of Clinical Trials for Organ-Repairing Molecule

  4/11/2019

  Repairing a damaged organ in order to allow an individual to have a healthier life, as well as a greater quality of life, could soon be a reality as New York-based Angion Biomedica Corp. moves toward completing clinical trials of its lead asset.

• Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater China

  11/12/2018

  Angion Biomedica and Sinovant Sciences today announced a collaboration and license agreement for BB3, Angion's investigational small molecule mimetic of hepatocyte growth factor (HGF), in the People's Republic of China, Hong Kong, Macau, and Taiwan (Greater China).

• Angion Biomedica Corp. Exclusively In-Licenses Aldosterone Synthase Inhibitors From ElexoPharm GmbH Complementing Its Ongoing Program In Chronic Kidney Disease

  6/22/2017

• Angion Biomedica Corp.'s Phase 2 “GUARD” Clinical Trial Of BB3 In Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study In Renal Transplant Recipients With Delayed Graft Function (DGF)

  1/31/2017